Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: A randomized, double-blind trial
Top Cited Papers
- 1 October 2004
- journal article
- clinical trial
- Published by Elsevier in Gastroenterology
- Vol. 127 (4) , 1123-1130
- https://doi.org/10.1053/j.gastro.2004.07.015
Abstract
No abstract availableKeywords
Funding Information
- Novo Nordisk
This publication has 26 references indexed in Scilit:
- Effects of the V1a vasopressin agonist F-180 on portal hypertension-related bleeding in portal hypertensive ratsHepatology, 2003
- Improving prognosis following a first variceal haemorrhage over four decadesGut, 2001
- Successful treatment with recombinant factor VIIa of therapy‐resistant severe bleeding in a patient with acquired von Willebrand diseaseAmerican Journal of Hematology, 2001
- Early Administration of Vapreotide for Variceal Bleeding in Patients with CirrhosisNew England Journal of Medicine, 2001
- Recombinant Activated Factor VII (rFVIIa) Acutely Normalizes Prothrombin Time in Patients with Cirrhosis During Bleeding from Oesophageal VaricesScandinavian Journal of Gastroenterology, 2001
- A predictive model for failure to control bleeding during acute variceal haemorrhageJournal of Hepatology, 1999
- Developing consensus in portal hypertensionJournal of Hepatology, 1996
- Definitions, methodology and therapeutic strategies in portal hypertension: A consensus development workshop, Baveno, Lake Maggiore, Italy, April 5 and 6, 1990Journal of Hepatology, 1992
- Prediction of the First Variceal Hemorrhage in Patients with Cirrhosis of the Liver and Esophageal VaricesNew England Journal of Medicine, 1988
- Transection of the oesophagus for bleeding oesophageal varicesBritish Journal of Surgery, 1973